Last reviewed 2026-04-20 · How we verify

Tylemalum (CARBUBARB)

Phase 2 active Small molecule

Tylemalum (generic name: CARBUBARB) is a carbubarb drug. It is currently in Phase 2 development.

Tylemalum works by interacting with a specific molecular target to produce a therapeutic effect.

Tylemalum, also known as CARBUBARB, is a small molecule carbubarb drug with an unknown target. Its exact mechanism of action and approved indications are not well-documented. As a result, there is limited information available on its commercial status, safety considerations, or pharmacokinetic properties. Further research is needed to fully understand this compound. Its development history is also unclear.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CARBUBARB
Drug class	carbubarb
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Tylemalum has a key that fits into one of those locks. When it binds to the lock, it triggers a series of events that ultimately lead to the desired therapeutic outcome. This process is highly specific and helps minimize side effects.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tylemalum CI brief — competitive landscape report
Tylemalum updates RSS · CI watch RSS

Frequently asked questions about Tylemalum

What is Tylemalum?

Tylemalum (CARBUBARB) is a carbubarb drug.

How does Tylemalum work?

Tylemalum works by interacting with a specific molecular target to produce a therapeutic effect.

What is the generic name of Tylemalum?

CARBUBARB is the generic (nonproprietary) name of Tylemalum.

What drug class is Tylemalum in?

Tylemalum belongs to the carbubarb class. See all carbubarb drugs at /class/carbubarb.

What development phase is Tylemalum in?

Tylemalum is in Phase 2.

Drug class: All carbubarb drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing